Insmed Inc

INSM

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

Global tensions drive profitability for ASX energy provider

Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks

ASX energy share undervalued ahead of earnings

Pricing strength outweighs temporary production headwinds.
stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,311.90125.801.37%
CAC 408,666.6352.810.61%
DAX 4026,202.35201.040.77%
Dow JONES (US)54,230.561,052.151.98%
FTSE 10010,879.3821.680.20%
HKSE25,852.92156.48-0.60%
NASDAQ26,607.00693.102.67%
Nikkei 22563,957.53202.630.32%
NZX 50 Index13,903.46128.530.93%
S&P 5007,748.14147.641.94%
S&P/ASX 2009,145.80122.801.36%
SSE Composite Index3,822.2812.620.33%

Market Movers